華東醫藥(000963.SZ):新一代智能美容設備雙極射頻抗衰設備“芮艾瑅®”(Reaction®)計劃2季度開始在國內銷售推廣
格隆匯4月18日丨華東醫藥(000963.SZ)於2023年4月14日15:00-16:00召開2022年度業績交流會,國內醫美業務,全資子公司欣可麗美學作為公司中國市場醫美業務運營中心,報吿期內合計實現營業收入6.26億元,並實現較好盈利。截至2022年底,欣可麗美學簽約合作醫院數量已超500家,培訓認證醫生數量超過1100人。
公司核心產品Ellansé®伊妍仕®憑藉再生及抗衰技術與理念,自中國市場上市以來,一直保持着較高的市場關注度,已成為國內醫美注射劑領域的明星產品,持續領跑國內醫美再生填充領域高端市場。2022年1季度,酷雪Glacial Spa®在國內成功完成了全球首發,目前已與國內超過40家美業機構開展商業化合作。Sinclair從愛爾蘭EMA Aesthetics獨家引入能量源設備——多功能面部皮膚管理平台Préime Derma Facial,已於2022年9月陸續在歐美等全球主要醫美市場實現商業化銷售,並計劃於2023年在中國上市;公司EBD產品—雙極射頻抗衰設備“芮艾瑅®”(Reaction®)為新一代的智能美容設備,已於2022年完成國內代理人變更,並計劃在2023年2季度開始在國內銷售推廣。聚左旋乳酸膠原蛋白刺激劑Lanluma®V型及X型於2022年12月獲批落地海南博鰲樂城,用於增加面部和身體凹陷區域的體積,尤其適用於矯正皮膚凹陷。2023年1季度MaiLi Extreme和Ellansé®伊妍仕®M型已分別順利完成中國臨牀試驗全部受試者入組,並已開始隨訪。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.